PPARD (peroxisome proliferator-activated receptor delta) by Astarci, E & Banerjee, S









Atlas Genet Cytogenet Oncol Haematol. 2010; 14(5)  470 
Atlas of Genetics and Cytogenetics 
in Oncology and Haematology 
OPEN ACCESS JOURNAL AT INIST-CNRS 
PPARD (peroxisome proliferator-activated 
receptor delta) 
Erhan Astarci, Sreeparna Banerjee 
Department of Biology, Middle East Technical University, Ankara 06531, Turkey (EA, SB) 
 
Published in Atlas Database: June 2009 
Online updated version : http://AtlasGeneticsOncology.org/Genes/PPARDID41794ch6p21.html 
DOI: 10.4267/2042/44757 
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 2.0 France Licence. 
© 2010 Atlas of Genetics and Cytogenetics in Oncology and Haematology 
 
Identity 
Other names: FAAR; MGC3931; NR1C2; NUC1; 
NUCI; NUCII; PPAR-beta; PPAR-delta; PPARB 
HGNC (Hugo): PPARD 
Location: 6p21.31 
Local order: According to NCBI Map Viewer, genes 
flanking PPAR delta in centromere to telomere 
direction on 6p21 are:  
- UHRF1BP1 (UHRF1 (ICBP90) binding protein 1) 
- ZNF76 (zinc finger protein 76 (expressed in testis)) 
- DEF6 (differentially expressed in FDCP 6 homolog 
(mouse)) 
- PPARD (peroxisome proliferator-activated receptor 
delta) 
- TULP1 (tubby like protein 1) 
- C6orf126 (chromosome 6 open reading frame 126). 
Note: PPAR delta is one of the orphan nuclear 
hormone receptors which were first identified as 
proteins that control the size and the numbers of 
peroxisomes by binding to the peroxisome 
proliferators. PPARs (classified as PPARalpha, 
PPARgamma and delta/beta) perform a number of 
functions and are implicated in several diseases such as 
obesity, diabetes, cancer and atherosclerosis. In 
comparison to the other peroxisome proliferators, 
PPAR delta protein is a potent inhibitor of PPAR alpha 




PPAR delta gene is located on chromosome 6p21-22. 
Description 
According to Entrez-Gene, PPARD gene maps to 
NC_000006.10 and spans a region of 10.7 kilo bases. 
According to Spidey (mRNA to genomic sequence 
alignment tool), PPAR delta has 8 exons, the sizes 
being 124, 84, 231, 155, 139, 203, 451, 2347. 
Transcription 
PPAR delta mRNA NM_006238 has 3734 bp.  
PPAR-delta is activated by either hypolipidemic drugs 
or fatty acids. The mammalian counterparts are 
particularly activated by 18C unsaturated fatty acids.  
According to GeneCards, PPAR delta expression was 
detected in 12 human tissues including spleen, thymus, 
brain, spinal cord, heart, skeletal cord, liver, pancreas, 
prostate, kidney and lung. 
  
PPAR delta gene diagram. Red boxes indicate the exons. Start and stop codons are shown by the two arrows respectively. 
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PPARD has two protein isoforms produced by 
alternative splicing. PPAR delta acts as a transcription 
factor in the presence of a ligand and after 
heterodimerization with the retinoid acid X receptor. 
Description 
PPARD protein is composed of 441 amino acids and 
has a molecular weight of 49.9 kDa. According to the
NCBI conserved domain search, the protein contains 
two zinc finger C4 type domains which is a conserved 
domain in proteins with DNA binding activity. The 
protein also has a flexible hinge region and a ligand 
binding domain near the C terminus. 
Expression 
PPAR delta is expressed in wide range of tissues and is 
highly expressed in spleen, thymus, brain, spinal cord, 
heart, skeletal cord, liver, pancreas, prostate, kidney 
and lung. 
Localisation 
Located in the nucleus. 
Function 
Similar to other peroxisome proliferator activated 
receptors PPAR delta is also involved in differentiation 
and metabolism. Fatty acid regulation and oxidation in 
skeletal muscle and adipose tissues is one of the major 
functions of PPAR delta. It has been shown that the 
increase in muscle oxidative capacity correlates 
positively with PPAR delta expression. Additionally, 
fatty acid efflux is also regulated by PPAR delta by 
redirection of the fatty acid ligand from the adipose 
tissue to the skeletal muscles which results in a 
decrease in the size of the adipose tissue. Fatty acids 
are natural ligands of the PPAR delta and it is know  
that its activity increases by certain eicosanoids l ke
leukotriene B4. 
Homology 
Canis familiaris: PPAR-beta, peroxisome proliferato-
activated receptor delta.  
Pan troglodytes: LOC463188, peroxisome proliferator-
activated receptor delta.  
Rattus norvegicus: Ppard, peroxisome proliferator 
activated receptor delta.  
Mus musculus: Ppard, peroxisome proliferator activator 
receptor delta.  
Gallus gallus: PPARD, peroxisome proliferator-






SNP rs1053049 rs6902123 rs2267668 are associated 
with insulin resistance.  
SNP rs2016520, rs3734254 and rs9794 are associated 
with obesity. 
Gly482Ser is associated with insulin resistance. 
-87T/C polymorphism is associated with alterations in 
cholesterol metabolism. 
-13454G>T, c.2022+12G>A, c.2629T>C, c.2806C>G 




PPARdelta is overexpressed in human colon cancers 
and genetic disruption of the gene in mice was shown 
to significantly reduce the incidence of colorectal 
cancer by reducing expression of vascular endothelial 
growth factor. Additionally, Wnt/beta-catenin has been 
shown to stimulate PPAR delta expression. Activation 
of the COX-2 pathway resulting in the production of 
prostaglandin E2 activated PPAR delta via the PI3K-
Akt pathway. PPAR delta can also cross talk with other 
transcription factors such as nuclear factor kappa B. 
PPAR delta is highly expressed in the gastrointestinal 
tract in a constitutive manner where it regulates cll
proliferation and differentiation. In mouse it has been 
shown that mouse PPAR delta has both ligand 
dependent and independent effects and ligand 
independent effects are involved in down regulation of 
inflammation whereas the ligand dependent effects 
include proliferation and differentiation. Contradicting 
results support that PPARdelta can induce or allevit  
the disease progression. 
Insulin resistance 
Disease 
Single nucleotide polymorphisms (SNPs) in the PPAR 
delta gene are associated with insulin resistance and 
increased fat storage due to an interference in 
mitochondrial functions. After having genotyped 156 
patients for the reference SNPs (rs) who are in the risk 
group for type 2 diabetes, they were shown to carry the 
SNPs rs1053049, rs6902123, and rs2267668 (A:A, 
A:G, A:G respectively) in the PPAR delta gene. 
Another study indicated that a (-87 T/C) polymorphism 
affects both plasma glucose levels in the fasting state, 
insulin sensitivity and cholesterol metabolism. Carriers 
with the C allele displayed increased plasma glucose 
levels and decreased insulin sensitivity with respect to 
the T allele carrying counterparts.  
Higher titer of low density lipoprotein was also  
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observed in the C allele carriers. It was also concluded 
that higher levels of fasting plasma glucose levels were 
independent from the etiology of being diabetic or 




Catabolism of fats has been shown to be regulated by 
PPAR delta which could thus be exploited as a 
potential target for the treatment of obesity and type-2 
diabetes. Of the nine polymorphic markers sequenced 
in the PPAR delta gene four polymorphisms were 
found in the intronic regions, one in an untranslated 
region and four in the 3' untranslated region (UTR). 
The polymorphisms were -13454G>T, c.-87T>C, 
c.2022+12G>A, c.2629T>C, and c.2806C>G. The 
same polymorphisms, however, were not significantly 
associated with the risk for Type 2 diabetes. However 
in terms of fasting plasma glucose levels and body 




As lipid metabolism is involved in atherogenesis, the 
effects PPARdelta expression in atherosclerotic 
changes in macrophages were investigated. It has been
shown that use of PPAR delta agonists reduces 
atherosclerosis in apoE double negative mice. The 
mechanism has been shown to be through elevation of 
high density lipoprotein level and suppression of 
inflammation possibly by the down regulation of 
chemokines which then results in a decrease in the 
chemoattractant signaling. PPARdelta activation is also 
associated with the increased expression of G-protein 
signaling genes which has been shown to block the 
chemokine receptors. 
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